GIP(6-30amide) contains the high affinity binding region of GIP and is a potent inhibitor of GIP1-42) action in vitro

Regulatory Peptides

Volumn 69, Issue 3, 1997, Pages 151-154

  Gelling, Richard W ^a   Coy, David H ^b   Pederson, Raymond A ^a   Wheeler, Michael B ^c   Hinke, Simon ^a   Kwan, Theresa ^a   McIntosh, Christopher H S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

CHO K1 cells; Cyclic AMP; GIP Receptor

Indexed keywords

CYCLIC AMP; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE[1-42]; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE[10-30]; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE[6-30]AMIDE; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE[7-30]; INSULIN; POLYPEPTIDE; RECEPTOR BLOCKING AGENT; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING COMPETITION; CHO CELL; CONTROLLED STUDY; INSULIN RELEASE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANIMALIA;

EID: 0030747857     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(97)00009-8     Document Type: Article

References (20)

1. Brown JC, Buchan AMJ, McIntosh CHS, Pederson RA. Gastric inhibitory polypeptide. In: Schultz SG, Makhlouf GM, Rauner BB, editors. Handbook of physiology, sect. 6. American Physiology Society, Bethesda, 1989:403-30.
2. Pederson RA. Gastric inhibitory polypeptide. In: Walsh J, Dockray G, editors. Gut peptides. New York: Raven Press, 1993:217-59.
3. Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 1994;107:1848-55.
4. Lauritsen KB, Holst JJ, Moody AJ. Depression of insulin release by anti-GIP serum after oral glucose in rats. Scand J Gastroenterol 1981;16:417-20.
5. Ebert R, Creutzfeldt W. Influence of gastric inhibitory polypeptide antiserum on glucose-induced insulin secretion in rats. Endocrinology 1982;111:1601-6.
6. Ebert R, Illmer K, Creutzfeldt W. Release of gastric inhibitory polypeptide (GIP) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP-antiserum in rats. Gastroenterology 1979;76:515-23.
7. Kolligs F, Fehmann H-C, Göke R, Göke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 1995;44:16-9.
8. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR. Glucagon-like peptide-1 is a physiological incretin in man. J Clin Invest 1995;95:417-21.
9. Wheeler MB, Gelling RW, Mcintosh CHS, Georgiu A, Brown JC, Pederson RA. Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties. Endocrinology 1995;136:4629-39.
10. Wheeler MB, Lu M, Dillon JS, Leng X-H, Chen C, Boyd III AE. Functional expression of the rat glucagon-like peptide-1 receptor, evidence for coupling to both adenylyl cyclase and phospholipase C. Endocrinology 1993;133:57-62.
11. Ebert R, Unger H, Creutzfeldt W Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption. Diabetologia 1983;24:449-54.
12. 1-38) with full insulinotropic activity. Scand J Gastroenterol 1978;13(Suppl 46):129.
13. Sandberg E, Ahren B, Tendler D, Carlquist M, Efendic S. Potentiation of glucose-induced insulin secretion in the perfused rat pancreas by porcine GIP (gastric inhibitory polypeptide), bovine GIP, and bovine GIP(1-39). Acta Physiol Scand 1986;127:323-6.
14. Maletti M, Altman JJ, Hoa DH, Carlquist M, Rosselin G. Evidence of functional gastric inhibitory polypeptide (GIP) receptors in human insulinoma. Binding of synthetic human GIP 1-31 and activation of adenylate cyclase. Diabetes 1987;36:1336-40.
15. Pederson RA, Mochizuki T, Yanaihara T, Yanaihara N, Brown JC. Reduced somatostatinotropic effect of a GIP fragment (pGIP( 1-30)-NH2) with insulinotropic activity. Diabetes 1990;46 Suppl 1:86.
16. Rossowski WJ, Zacharia S, Mungan Z, Ozmen V, Ertan A, Baylor LM, Jiang N-Y, Coy DH. Reduced gastric acid inhibitory effect of a pGIP(1-30)NH2 fragment with potent pancreatic amylase inhibitory activity. Regul Pept 1992;39:9-17.
17. Maletti M, Carlquist M, Portha B, Kergoat M, Mutt V, Rosselin G. Structural requirements for gastric inhibitory polypeptide (GIP) receptor binding and stimulation of insulin release. Peptides 1986;7(Suppl 1):75-8.
18. Carlquist MM, Maletti M, Jörnvall H, Mutt V. A novel form of gastric inhibitory polypeptide (GIP) isolated from bovine intestine using a radioreceptor assay. Fragmentation with staphylococcal protease results in GIP 1-3, GIP 4-42, fragmentation with enterokinase in GIP 1-16 and GIP 17-42. Eur J Pharmacol 1984;145:573-7.
19. Morrow GW, Kieffer TJ, McIntosh CHS, MacGillivray RTA, Brown JC, StPierre S, Pederson RA. The insulinotropic region of gastric inhibitory polypeptide; fragment analysis suggests the bioactive site lies between residues 19 and 30. Can J Physiol Pharmacol 1996;74:65-72.
20. Tseng C-C, Kieffer TJ, Jarboe LA, Usdin TB, Wolfe MM. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP): Effect of a specific GIP receptor antagonist. Regul Pept 1996;64:194.